RDGL VIVOS INC

Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India

Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India

Kennewick, WA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL)

The Vivos Board granted authorization to form a wholly owned corporate subsidiary in India. Vivos Inc filed for the name of Vivos Scientific India LLP. Vivos is completing the steps remaining to obtain formal approvals from the Indian government.

“This demonstrates our long-term commitment to doing business in India and supports our long-term plan of establishing our first international manufacturing center for RadioGel and IsoPet, for expanding our developmental animal testing, and for commercially treating humans and animals in India.”

India is an important region for us, having initiated first in human trials, which we announced in December of 2024. We are actively pursuing DCGI (Drug Controller General of India) approval for additional expanded human trials in India. As we have previously stated, we believe our India trials are supportive of our IDE process with the FDA. Based on feedback from the FDA, as part of our IDE application process, our formal protocol for the next phase of human trials in India will include immediate post treatment PET full- body scans to further validate RadioGel’s safety profile.

Michael K. Korenko, Sc.D.

CEO, Vivos Inc.

Email:

Follow Vivos Inc. on X (Twitter): @VivosIncUSA

Learn more about RadioGel® and IsoPet® at

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, identified by terms such as “will,” “expects,” “plans,” “anticipates,” and “intends.” These statements involve risks and uncertainties that may cause actual results to differ materially, including challenges in executing business strategies, economic conditions, competition, regulatory changes, delays in clinic certifications, and other factors beyond Vivos Inc.’s control. For a detailed discussion of these risks, refer to the company’s filings with the Securities and Exchange Commission.



EN
29/09/2025

Underlying

RDGLVIVOS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on VIVOS INC

 PRESS RELEASE
Free
RDGL VIVOS INC

Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and Intern...

Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites Kennewick, WA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering its innovative RadioGel® Radionuclide Therapy™ (PRnT™) is preparing to open two new production facilities. Previous corporate filings have included risk factors regarding the Company’s continued use of a single production site. For the past two years, the Company has been assessing alternate facilities. The Company’s strategic target is to have one domestic production facility, in whic...

February 17, 2026 1 EN
 PRESS RELEASE
Free
RDGL VIVOS INC

Vivos Inc. Announces Significant Progress Toward FDA Investigational D...

Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ Kennewick, WA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT™) with its innovative RadioGel® technology, today provided an update on its ongoing efforts to secure FDA Investigational Device Exemption (IDE) approval for human clinical trials of RadioGel® in advanced human therapy applications. RadioGel® is a targeted radiation therapy designed to deliver p...

February 10, 2026 1 EN
 PRESS RELEASE
Free
RDGL VIVOS INC

Vivos Inc Updates Human Therapy Progress in India

Vivos Inc Updates Human Therapy Progress in India Kennewick, WA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to provide shareholders with a positive update on the ongoing human therapy demonstrations in India using RadioGel® Precision Radionuclide Therapy™. Initiated in December 2024, a prominent physician in India began treating patients to demonstrate safety and measure efficacy with RadioGel®. Patients have continued to attend their scheduled regulatory follow-up visits in accordance with the protocol. To date, no reports of serious adverse events have been ...

February 3, 2026 1 EN
 PRESS RELEASE
Free
RDGL VIVOS INC

Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance...

Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals Kennewick, WA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a pioneer in innovative cancer treatment technologies, announces the issuance of U.S. Patent No. 12,521,452 B2 by the United States Patent and Trademark Office (USPTO), titled “Radiotherapy Gel and Method of Preparing the Same.” The patent, granted on January 13, 2026, protects critical advancements in the company’s proprietary Precision Radionuclide TherapyTM (PRnT) platform, underpinning its flagship produ...

January 28, 2026 1 EN
 PRESS RELEASE
Free
RDGL VIVOS INC

Vivos Inc Summarizes Progress in its Animal Therapy Division

Vivos Inc Summarizes Progress in its Animal Therapy Division Kennewick, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The IsoPet division reported a 1,200% year-over-year increase in administered therapies from 2024 to 2025, reflecting accelerating veterinary adoption nationwide. In recent months, the Company has seen a sharp rise in inbound inquiries from both veterinarians and pet owners seeking access to IsoPet therapy, signaling growing awareness and demand for this precise, cost-effective alternative to traditional radiation. Starting in Q1 2026, the division will im...

December 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch